Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial
- PMID: 33367487
- DOI: 10.1093/ehjcvp/pvaa140
Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial
Abstract
Aims: Whether diabetes without insulin therapy is an independent cardiovascular (CV) risk factor in atrial fibrillation (AF) has recently been questioned. We investigated the prognostic relevance of diabetes with or without insulin treatment in patients in the ARISTOTLE trial.
Methods and results: Patients with AF and increased stroke risk randomized to apixaban vs. warfarin were classified according to diabetes status: no diabetes; diabetes on no diabetes medications; diabetes on non-insulin antidiabetic drugs only; or insulin-treated. The associations between such patient subgroups and stroke/systemic embolism (SE), myocardial infarction (MI), and CV death were examined by Cox proportional hazard regression, both unadjusted and adjusted for other prognostic variables. Patients with diabetes were younger and had a higher body mass index. Median CHA2DS2VASc score was 4.0 in patients with diabetes and 3.0 in patients without diabetes. We found no significant difference in stroke/SE incidence across patient subgroups. Compared with no diabetes, only insulin-treated diabetes was significantly associated with higher risk. When adjusted for clinical variables, compared with no diabetes, the hazard ratios (HRs) for MI (95% confidence intervals) were for diabetes on no medication: 1.15 (0.62-2.14); for diabetes on non-insulin antidiabetic drugs: 1.32 (0.90-1.94); for insulin-treated diabetes: 2.34 (1.43-3.82); interaction P = 0.008. HRs for CV death were for diabetes on no medication: 1.19 (0.86-166); for diabetes on non-insulin antidiabetic drugs: 1.12 (0.88-1.42); for insulin-treated diabetes 1.85 (1.36-2.53), interaction P = 0.001.
Conclusion: In anticoagulated patients with AF, a higher risk of MI and CV death is largely confined to diabetes treated with insulin.
Keywords: Atrial fibrillation; Death; Diabetes; Insulin; Myocardial infarction; Stroke.
© The Author(s) 2020. Published on behalf of the European Society of Cardiology.
Similar articles
-
Heterogeneity of outcomes within diabetic patients with atrial fibrillation on edoxaban: a sub-analysis from the ETNA-AF Europe registry.Clin Res Cardiol. 2023 Nov;112(11):1517-1528. doi: 10.1007/s00392-022-02080-5. Epub 2022 Aug 17. Clin Res Cardiol. 2023. PMID: 35976428 Free PMC article.
-
N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation).J Am Coll Cardiol. 2013 Jun 4;61(22):2274-84. doi: 10.1016/j.jacc.2012.11.082. Epub 2013 Apr 3. J Am Coll Cardiol. 2013. PMID: 23563134 Clinical Trial.
-
High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin.J Am Coll Cardiol. 2014 Jan 7-14;63(1):52-61. doi: 10.1016/j.jacc.2013.07.093. Epub 2013 Sep 19. J Am Coll Cardiol. 2014. PMID: 24055845 Clinical Trial.
-
Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation.Circulation. 2018 Oct 2;138(14):1402-1411. doi: 10.1161/CIRCULATIONAHA.117.031457. Circulation. 2018. PMID: 29794081
-
Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence.Hosp Pract (1995). 2011 Oct;39(4):7-16. doi: 10.3810/hp.2011.10.918. Hosp Pract (1995). 2011. PMID: 22056819 Review.
Cited by
-
Diabetes and Thrombosis: A Central Role for Vascular Oxidative Stress.Antioxidants (Basel). 2021 Apr 29;10(5):706. doi: 10.3390/antiox10050706. Antioxidants (Basel). 2021. PMID: 33946846 Free PMC article.
-
Our knowledge about atrial fibrillation steadily increases.Eur Heart J Cardiovasc Pharmacother. 2025 Aug 12;11(5):397-398. doi: 10.1093/ehjcvp/pvaf050. Eur Heart J Cardiovasc Pharmacother. 2025. PMID: 40796150 Free PMC article. No abstract available.
-
Prognostic significance of diabetes mellitus in patients with atrial fibrillation.Cardiovasc Diabetol. 2021 Feb 11;20(1):40. doi: 10.1186/s12933-021-01232-7. Cardiovasc Diabetol. 2021. PMID: 33573666 Free PMC article.
-
Heterogeneity of outcomes within diabetic patients with atrial fibrillation on edoxaban: a sub-analysis from the ETNA-AF Europe registry.Clin Res Cardiol. 2023 Nov;112(11):1517-1528. doi: 10.1007/s00392-022-02080-5. Epub 2022 Aug 17. Clin Res Cardiol. 2023. PMID: 35976428 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical